Odomzo price?

What’s the list price of Odomzo?
Odomzo (ocrelizumab) carries a list price of about $74,500 per year, which reflects the cost of a full treatment course under typical insurance contracts. [1]

How does insurance usually treat Odomzo payments?
Most commercial plans cover Odomzo under specialty drug tiers, but patients often pay a copay or coinsurance ranging from 10 % to 30 % of the list price. Pharmacy‑benefit managers usually negotiate a lower formulary price, so the out‑of‑pocket amount can be substantially less than the published figure.

What if I’m on Medicare?
Medicare Part D plans generally list Odomzo in the specialty drug tier. The copay or coinsurance depends on the specific plan; some plans offer a 25 % coinsurance on the Medicare-approved amount, which is typically lower than the list price.

Are there patient assistance or copay help programs?
The manufacturer offers a Patient Assistance Program that can cover up to 100 % of the copay for patients who qualify, and a Copay Relief card provides monthly savings on prescription fees. Eligibility depends on income, insurance status, and medical need.

What alternatives are available and how do their costs compare?
Other monoclonal antibodies for multiple sclerosis, such as ocrelizumab (Ocrevus) and natalizumab (Tysabri), have similar annual list prices—generally in the $70,000–$80,000 range—though the actual out‑of‑pocket costs vary with insurance and program participation.

When does Odomzo’s patent protection end?
The core ocrelizumab antibody patent expires in 2034, but secondary patents covering formulation and delivery may extend exclusivity until 2040. The extended protection limits generic or biosimilar entry for several years.

Can biosimilars enter before the patent expires?
Not before 2034, because the antibody platform remains protected. Even after the primary patent lapses, regulatory and market barriers could delay biosimilar approval and commercial launch.

Is there any recent litigation affecting Odomzo pricing?
No major patent disputes have surfaced that would alter the pricing structure or market dynamics as of the latest public filings.

How do patients typically manage the high cost?
Most patients rely on a combination of insurance coverage, manufacturer assistance, and, in some cases, state prescription assistance funds. In addition, patient advocacy groups often help navigate these resources.

---

Sources

[1] DrugPatentWatch.com – Odomzo (ocrelizumab) pricing information.